Adrenergic beta-2 Receptor Agonists
"Adrenergic beta-2 Receptor Agonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds bind to and activate ADRENERGIC BETA-2 RECEPTORS.
| Descriptor ID |
D058666
|
| MeSH Number(s) |
D27.505.519.625.050.100.200.200 D27.505.696.577.050.100.200.200
|
| Concept/Terms |
Adrenergic beta-2 Receptor Agonists- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta 2 Receptor Agonists
- Adrenergic beta2-Agonists
- Adrenergic beta2 Agonists
- beta2-Agonists, Adrenergic
- Adrenergic beta-2 Agonists
- Adrenergic beta 2 Agonists
- Agonists, Adrenergic beta-2
- beta-2 Agonists, Adrenergic
- Adrenergic beta-2 Receptor Agonist
- Adrenergic beta 2 Receptor Agonist
|
Below are MeSH descriptors whose meaning is more general than "Adrenergic beta-2 Receptor Agonists".
Below are MeSH descriptors whose meaning is more specific than "Adrenergic beta-2 Receptor Agonists".
This graph shows the total number of publications written about "Adrenergic beta-2 Receptor Agonists" by people in this website by year, and whether "Adrenergic beta-2 Receptor Agonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 1 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 2 | 3 |
| 2011 | 1 | 2 | 3 |
| 2012 | 3 | 1 | 4 |
| 2013 | 3 | 3 | 6 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 2 | 0 | 2 |
| 2017 | 2 | 3 | 5 |
| 2018 | 5 | 0 | 5 |
| 2021 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adrenergic beta-2 Receptor Agonists" by people in Profiles.
-
Characterization of Moderate and Severe Asthma Exacerbations in the CAPTAIN Study. J Allergy Clin Immunol Pract. 2024 Sep; 12(9):2372-2380.e5.
-
Cardiovascular Events with the Use of Long-Acting Muscarinic Receptor Antagonists: An Analysis of the FAERS Database 2020-2023. Lung. 2024 04; 202(2):119-125.
-
Clinical characteristics and healthcare resource utilization in patients with chronic obstructive pulmonary disease in Hong Kong. Respir Med. 2024 02; 222:107516.
-
Beta Agonists for Prevention of Respiratory Adverse Events in Children Undergoing Adenotonsillectomy: Long-Acting, Short Acting, or Not Acting. Anesth Analg. 2023 06 01; 136(6):1064-1066.
-
Bronchodilators in Tobacco-Exposed Persons with Symptoms and Preserved Lung Function. N Engl J Med. 2022 09 29; 387(13):1173-1184.
-
Perplexing mortality data from triple therapy trials in COPD - Author's reply. Lancet Respir Med. 2021 10; 9(10):e96.
-
Future concepts in bronchodilation for COPD: dual- versus monotherapy. Eur Respir Rev. 2021 Jun 30; 30(160).
-
?2-Adrenergic receptor agonist induced hepatic steatosis in mice: modeling nonalcoholic fatty liver disease in hyperadrenergic states. Am J Physiol Endocrinol Metab. 2021 07 01; 321(1):E90-E104.
-
Letter to editor - a response to: 'efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review'. Expert Opin Pharmacother. 2021 05; 22(7):939-941.
-
Inhaled Medication Use in Smokers With Normal Spirometry. Respir Care. 2021 Apr; 66(4):652-660.